1. Home
  2. DLPN vs LYRA Comparison

DLPN vs LYRA Comparison

Compare DLPN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • LYRA
  • Stock Information
  • Founded
  • DLPN N/A
  • LYRA 2005
  • Country
  • DLPN United States
  • LYRA United States
  • Employees
  • DLPN N/A
  • LYRA N/A
  • Industry
  • DLPN Other Consumer Services
  • LYRA Medical/Dental Instruments
  • Sector
  • DLPN Consumer Discretionary
  • LYRA Health Care
  • Exchange
  • DLPN Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • DLPN 12.9M
  • LYRA 11.0M
  • IPO Year
  • DLPN N/A
  • LYRA 2020
  • Fundamental
  • Price
  • DLPN $1.11
  • LYRA $0.17
  • Analyst Decision
  • DLPN Strong Buy
  • LYRA Buy
  • Analyst Count
  • DLPN 1
  • LYRA 5
  • Target Price
  • DLPN $5.00
  • LYRA $4.50
  • AVG Volume (30 Days)
  • DLPN 49.8K
  • LYRA 1.7M
  • Earning Date
  • DLPN 11-14-2024
  • LYRA 11-12-2024
  • Dividend Yield
  • DLPN N/A
  • LYRA N/A
  • EPS Growth
  • DLPN N/A
  • LYRA N/A
  • EPS
  • DLPN N/A
  • LYRA N/A
  • Revenue
  • DLPN $51,389,626.00
  • LYRA $1,471,000.00
  • Revenue This Year
  • DLPN $21.74
  • LYRA N/A
  • Revenue Next Year
  • DLPN $7.26
  • LYRA N/A
  • P/E Ratio
  • DLPN N/A
  • LYRA N/A
  • Revenue Growth
  • DLPN 21.66
  • LYRA 3.37
  • 52 Week Low
  • DLPN $0.95
  • LYRA $0.16
  • 52 Week High
  • DLPN $3.58
  • LYRA $6.79
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 45.36
  • LYRA 36.11
  • Support Level
  • DLPN $1.02
  • LYRA $0.19
  • Resistance Level
  • DLPN $1.20
  • LYRA $0.21
  • Average True Range (ATR)
  • DLPN 0.09
  • LYRA 0.02
  • MACD
  • DLPN -0.00
  • LYRA -0.00
  • Stochastic Oscillator
  • DLPN 26.47
  • LYRA 6.42

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: